Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | Plasma cells | -0.308951 | 9.32e-33 |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre | Plasma cells | 0.356476 | 1.97e-20 |
GSE212217 | patients | Peripheral blood mononuclear cells | Endometrial cancer | Epigenetic MMRd endometrial carcinoma | Immunotherapy | pembrolizumab | post | Plasma cells | 0.448331 | 1.54e-04 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | pre | Malignant cells | 0.888827 | 2.20e-07 |
GSE161195 | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone) | pre | Malignant cells | -0.324492 | 0.00e+00 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post | NK cells | -0.373576 | 8.73e-42 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post | CD8+ T cells | -0.330756 | 6.10e-35 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | pre | B cells | 1.57132 | 7.19e-11 |
GSE131984_JQ1 | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 | NA | Malignant cells | -0.330859 | 6.23e-14 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | post | Malignant cells | -0.255116 | 0.00e+00 |
GSE175716 | PDX | Tumor tissue | Liver cancer | Advanced hepatocellular carcinoma | Targeted therapy | sorafenib | NA | Malignant cells | -0.285003 | 5.71e-31 |
GSE164897_VemCob | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib + combimetinib | NA | Malignant cells | -0.264403 | 0.00e+00 |
Gene symbol | motif | TF_highConf |
FKBP11 | taipale_tf_pairs__ETS2_RCCGGAAGTG_HT | ETS2 (directAnnotation). |
FKBP11 | hdpi__FLI1 | FLI1 (directAnnotation). |
FKBP11 | metacluster_22.12 | NFE2; NFE2L1 (directAnnotation). |
FKBP11 | metacluster_14.28 | CLOCK (inferredBy_Orthology). |
FKBP11 | metacluster_22.29 | NFE2 (directAnnotation). |
FKBP11 | taipale_tf_pairs__FOXO1_ELK1_RSCGGATGTTRTN_CAP | ELK1; FOXO1 (directAnnotation). |
FKBP11 | metacluster_22.21 | NFE2L2 (inferredBy_Orthology). |
FKBP11 | taipale_tf_pairs__ELK1_HOXA1_RCCGGAAGTAATTA_HT | ELK1; HOXA1 (directAnnotation). |
FKBP11 | metacluster_166.4 | BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology). |
FKBP11 | metacluster_22.13 | MAFK (inferredBy_Orthology). |
FKBP11 | taipale_tf_pairs__GCM1_ETV4_RTGCGGGCGGAAGTR_CAP | ETV4; GCM1 (directAnnotation). |
FKBP11 | taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP | ELK3; FOXO1 (directAnnotation). |
FKBP11 | transfac_pro__M05605 | GATA6 (inferredBy_Orthology). |
FKBP11 | taipale_tf_pairs__ETV2_FOXO6_RCCGGATGTTKWN_CAP | ETV2; FOXO6 (directAnnotation). |
FKBP11 | taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT | ELF2 (directAnnotation). |
FKBP11 | taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP | ETV5; HOXA2 (directAnnotation). |
FKBP11 | metacluster_22.32 | NFE2L2 (directAnnotation). |
FKBP11 | transfac_pro__M04844 | MAX (directAnnotation). |
FKBP11 | taipale_tf_pairs__ERF_FOXI1_RSCGGATGTTKWN_CAP_repr | ERF; FOXI1 (directAnnotation). |
FKBP11 | transfac_pro__M01116 | ARNTL; ARNTL2 (directAnnotation). |
FKBP11 | metacluster_10.30 | MXI1 (inferredBy_Orthology). |
FKBP11 | metacluster_10.46 | MAX (inferredBy_Orthology). |
FKBP11 | metacluster_139.7 | XBP1 (directAnnotation). XBP1 (inferredBy_Orthology). |
FKBP11 | transfac_pro__M06609 | ZKSCAN4 (directAnnotation). |
FKBP11 | taipale_tf_pairs__TEAD4_ELK1_RGAATSCGGAAGYN_CAP_repr | ELK1; TEAD4 (directAnnotation). |
FKBP11 | metacluster_10.48 | ID2 (inferredBy_Orthology). |
FKBP11 | flyfactorsurvey__Max_Mnt_SANGER_5_FBgn0017578 | MAX (inferredBy_Orthology). |
FKBP11 | metacluster_14.8 | MLX (directAnnotation). |
FKBP11 | homer__NVCACGTG_NPAS | NPAS2 (inferredBy_Orthology). |
FKBP11 | cisbp__M05832 | MAX (directAnnotation). |
FKBP11 | taipale_tf_pairs__MYCL2_SCACGTGS_HT | MYCLP1 (directAnnotation). |
FKBP11 | metacluster_10.39 | NPAS2 (inferredBy_Orthology). |
FKBP11 | hocomoco__MLX_HUMAN.H11MO.0.D | MLX (directAnnotation). |
FKBP11 | metacluster_143.19 | PLAGL2; ZNF740 (directAnnotation). |
FKBP11 | metacluster_10.17 | ARNT (inferredBy_Orthology). |
FKBP11 | metacluster_14.13 | MAX; USF1; USF1 (directAnnotation). |
FKBP11 | transfac_pro__M06282 | ZSCAN10 (inferredBy_Orthology). |
FKBP11 | transfac_pro__M06172 | ZNF90 (directAnnotation). |
FKBP11 | swissregulon__hs__CLOCK | CLOCK (directAnnotation). |
FKBP11 | tfdimers__MD00599 | NR1I2; RXRA; STAT1 (directAnnotation). |
FKBP11 | tfdimers__MD00384 | IKZF2; STAT1 (directAnnotation). |
FKBP11 | metacluster_191.3 | EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology). |
FKBP11 | metacluster_191.2 | ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology). |
FKBP11 | metacluster_166.2 | ELK4; ETS1; ETS1; ETV1; ETV3; ETV4; ETV5; ETV7 (directAnnotation). GABPA (inferredBy_Orthology). |
FKBP11 | taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr | ELF1; MEIS1 (directAnnotation). |
FKBP11 | jaspar__MA1483.2 | ELF2 (directAnnotation). |
FKBP11 | taipale_tf_pairs__ETV5_FOXI1_RSCGGATGTTGN_CAP | ETV5; FOXI1 (directAnnotation). |
FKBP11 | taipale_tf_pairs__ELK1_FOXI1_RSCGGATGTKKN_CAP | ELK1; FOXI1 (directAnnotation). |
FKBP11 | cisbp__M02645 | ETS1 (directAnnotation). |
FKBP11 | jaspar__MA1708.1 | ETV7 (directAnnotation). |
1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |